1 Erratum to: BioDrugs (2016) 30:371–378 DOI 10.1007/s40259-016-0188-z
Page 375, column 2, section 5, paragraph 3, lines 398–404: The following sentence, which previously read:
“At week 24, the incidence of injection-site reactions was comparable at week 52 [3.7 % of etanercept (SB4) recipients vs. 17.5 % reference etanercept recipients] [18].”
should read:
“The incidence of injection-site reactions at week 52 [3.7 % of etanercept (SB4) recipients vs. 17.5 % reference etanercept recipients] was consistent with that seen at week 24 [18].”
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40259-016-0188-z.
Rights and permissions
About this article
Cite this article
Burness, C.B., Duggan, S.T. Erratum to: Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases. BioDrugs 30, 481 (2016). https://doi.org/10.1007/s40259-016-0195-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40259-016-0195-0